NSE filing, NSE: CURIS. Summary written from the filing by ALFA Finder's alert engine.
Curis Lifesciences Ltd: key numbers
- Share price
- ₹181.50
- Market cap
- ₹146.7 Cr
- Revenue (annual)
- ₹60.63 Cr
- Net profit (annual)
- ₹6.92 Cr
- P/E (TTM)
- 21.2×Sector 46.1×
- Promoter holding
- 68.03%
- FII holding
- 1.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Curis Lifesciences Ltd
All →Curis Lifesciences Other Announcement
Curis Lifesciences Limited informed that it is not required to submit a Corporate Governance Report, as its securities are listed on the SME platform.
Curis Lifesciences Annual General Meeting
Curis Lifesciences Limited conducted its 10th Annual General Meeting on September 29, 2026, to transact various agenda items, including financial statement adoption and director appointments.
Curis Lifesciences Annual General Meeting
Curis Lifesciences filed its 10th AGM notice and FY 2025-26 Annual Report. The meeting is scheduled for September 29, 2026.
Curis Lifesciences Management Change
Curis Lifesciences Limited announced the resignation of Mr. Nikhil Purohit as Company Secretary and Compliance Officer, effective September 3, 2026.
Curis Lifesciences Other Announcement
Curis Lifesciences Limited submitted the RTA confirmation certificate for the quarter ended June 30, 2026, as required under SEBI Regulation 74(5).
Curis Lifesciences Merger & Restructuring Worth ₹0.05 Cr
Curis Lifesciences Limited has acquired a 49.95% stake in CUROSUN PHARMACEUTICAL NIG LTD, Nigeria, for Rs. 5 Lakhs to expand its pharmaceutical market presence.
- Value
- ₹0.05 Cr
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.